Cognitive improvement of acetylcholinesterase inhibitors in schizophrenia
González-Fraile, Eduardo (1)
Rueda, Jose R.
Tipo de Ítem:Articulo Revista Indexada
Background: Schizophrenia is a severe, persistent mental disorder, and a leading cause of disability worldwide. Cognitive impairments presented in schizophrenia lead to a worse prognostic, thus treatments targeted to enhance cognition in schizophrenia may be clinically relevant. Aims: The purpose of this study was to assess the efficacy of acetylcholinesterase inhibitors as add-on medication to antipsychotics on cognition in patients with schizophrenia. Methods: Search strategies were developed for Medline, Embase and Cochrane Central Register of Controlled Trials, and are current to March 2018. We included randomised controlled trials that compared antipsychotics plus acetylcholinesterase inhibitors versus antipsychotics plus placebo on prespecified cognitive domains (speed of processing, attention and working memory). Two review authors independently evaluated study eligibility, extracted data and assessed the risk of bias of included studies. We used random-effects model for meta-analyses and assessed the quality of evidence using Grading of Recommendations Assessment, Development and Evaluation (GRADE). Results: We included nine randomised controlled trials. Six randomised controlled trials (n=219) presented evidence that acetylcholinesterase inhibitors improve speed of processing (standardised mean difference -0.52, 95% confidence interval (-0.79 to -0.25); p value=0.0002). However, eight randomised controlled trials (n=252) did find placebo was better than acetylcholinesterase inhibitors in the attention domain (-0.43, (-0.72 to -0.13); p value=0.005) and eight randomised controlled trials (n=273) did not find differences in the working memory (-0.14, (-0.51 to 0.24), p value=0.47). Conclusions: The current evidence is too weak to base recommendations on the use of acetylcholinesterase inhibitors as adjunctive treatments to antipsychotics to improve basic cognitive functions. We have limited confidence in the effect estimates.
Este ítem aparece en la(s) siguiente(s) colección(es)
Mostrando ítems relacionados por Título, autor o materia.
Assessment of the consequences of caregiving in psychosis: a psychometric comparison of the Zarit Burden Interview (ZBI) and the Involvement Evaluation Questionnaire (IEQ) Gonçalves-Pereira, Manuel; González-Fraile, Eduardo (1); Santos-Zorrozua, Borja; Martín-Carrasco, Manuel; Fernández-Catalina, Paola; Domínguez-Panchón, Ana I; Muñoz-Hermoso, Paula; Ballesteros, Javier (Health and Quality of Life Outcomes, 04/2017)Background: The Zarit Burden Interview ( ZBI) was originally developed to assess the level of subjective burden in caregivers of people with dementia. The Involvement Evaluation Questionnaire ( IEQ) is amongst the leading ...
Mental health professionals’ attitudes towards mental illness: professional and cultural factors in the INTER NOS study Olmo-Romero, Francisco del; González-Blanco, María; Sarró, Salvador; Grácio, Jaime; Martín-Carrasco, Manuel; Martínez-Cabezón, Ana C; Giampaola, Perna; Pomarol-Clotet, Edith; Varandas, Pedro; Ballesteros-Rodríguez, Javier; Rebolleda-Gil, Carlos; Vanni, Giovanna; González-Fraile, Eduardo (1) (European Archives of Psychiatry and Clinical Neuroscience, 2018)BACKGROUND: Research shows that personnel working in mental health facilities may share some of the societal prejudices towards mental illness. This might result in stigmatizing behaviours towards people suffering from ...
Efficacy of mebendazole in paediatric patients with giardiasis: A systematic review and meta-analysis Escobedo, Angel A.; Almirall, Pedro; González-Fraile, Eduardo (1); Ballesteros, Javier (Acta Tropica, 12/2018)Mebendazole (MBZ), a benzimidazole compound, has received attention in treating patients with giardiasis because it has shown beneficial effects both in vitro and in vivo. The aim of this study was to assess with a systematic ...